Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…
Abstract Number: 1564 • 2015 ACR/ARHP Annual Meeting
Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Kaleb Michaud³, Grant W. Cannon⁴, Said Ibrahim⁵, Liron Caplan⁶, Lisa A. Davis⁶, Amy C. Cannella⁷ and Ted R. Mikuls⁸, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁴Internal Medicine, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Section of Rheumatology, University of Nebraska Med Ctr, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Low body mass index (BMI) predicts adverse outcomes in rheumatoid arthritis (RA), in part due to weight loss among patients with severe disease and…
Abstract Number: 1653 • 2015 ACR/ARHP Annual Meeting
Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis
Leslie Harrold^1,2, J. Lynn Palmer³, Jeffrey R. Curtis⁴, Jeffrey D. Greenberg^2,5 and Joel M. Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Corrona Research Foundation, Albany, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵NYU School of Medicine, New York, NY, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There is a growing emphasis on treating patients to a target level of low disease activity (LDA) or remission to order to improve outcomes…
Abstract Number: 429 • 2015 ACR/ARHP Annual Meeting
Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴, Carter Thorne⁵, VP Bykerk⁶, Andrew Thompson⁷, Diane Tin⁸ and Deborah Marshall⁹, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, St Joseph's Hlth Ctr, London, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada
Background/Purpose: Treatment choices in early rheumatoid arthritis need to balance benefits, risks, and other considerations such as dosing and monitoring. The objective of this study…
Abstract Number: 2269 • 2015 ACR/ARHP Annual Meeting
Rheumatologists Consider Patient Preferences and Costs When Choosing Treatments for Rheumatoid Arthritis (RA) Patients. a Cross-European Discrete Choice Experiment
Monika Hifinger¹, Mickaël Hiligsmann², Sofia Ramiro³, Verity Watson⁴, Johan L. Severens⁵, Bruno Fautrel⁶, Loreto Carmona⁷, Till Uhlig⁸, Ronald van Vollenhoven⁹, Peggy Jacques¹⁰, Jacqueline Detert¹¹, Carlo Alberto Scirè¹², Florian Berghea¹³, Márta Péntek¹⁴, Jose canas Silva¹⁵, Andrew Keat¹⁶ and Annelies Boonen¹⁷, ¹Rheumatology, University of Maastricht, Maastricht, Netherlands, ²Department of Health Services Research, University of Maastricht, Maastricht, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Health Economics Research Unit, University of Aberdeen, Aberdeen, United Kingdom, ⁵Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁷Instituto de Salud Musculoesqueletica, Madrid, Spain, ⁸Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁹Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ¹⁰University Hospital Ghent, Ghent, Belgium, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹²Italian Society for Rheumatology, Milan, Italy, ¹³Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, ¹⁴Corvinus University of Budapest, Budapest, Hungary, ¹⁵Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ¹⁶Northwick Park Hospital, Harrow, United Kingdom, ¹⁷Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Economic considerations and patient preferences are increasingly important when choosing treatments. It is not known to what extent rheumatologists across Europe account for these…
Abstract Number: 431 • 2015 ACR/ARHP Annual Meeting
Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission
Gülsah Akdemir¹, Iris M. Markusse², Johannes H.L.M. van Groenendael³, André J. Peeters⁴, Esmeralda T. Molenaar⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, T. W. J. Huizinga¹ and Cornelia F. Allaart¹, ¹Rheumatology, LUMC, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁴Rheumatology, RDGG, Delft, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Rheumatology, Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: To compare physicians' opinion on and adherence to treatment study protocols targeted at either Disease Activity Score (DAS) ≤2.4 or <1.6. Methods: The BeSt…
Abstract Number: 2313 • 2015 ACR/ARHP Annual Meeting
Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)
Vibeke Strand¹, Regina Rendas-Baum², George J. Joseph³, Chieh-I Chen⁴, Hubert van Hoogstraten⁵, T. W. J. Huizinga⁶ and Mark C. Genovese⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²QualityMetric Inc, Lincoln, RI, ³Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R), administered subcutaneously (SC) every 2 weeks (q2w). In the phase…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2491 • 2015 ACR/ARHP Annual Meeting
Documentation of Disease Activity Score As Part of a Treat to Target Strategy in Rheumatoid Arthritis
Sarah Homann¹ and Beth Scholz², ¹Rheumatology, University of Texas Health Sciences Center at Houston, Houston, TX, ²University of Texas Health Sciences Center at Houston, Houston, TX
Background/Purpose: Compared to routine care, the Treat to Target (TTT) strategy for rheumatoid arthritis (RA) has been validated to improve functional and radiographic outcomes via…
Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Boulos Haraoui¹, Louis Coupal², Radmila Day³, Lionel Budry⁴ and Youb Chalabi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ³None, Montreal, QC, Canada, ⁴Bristol Myers Squibb Canada, St-Laurent, QC, Canada, ⁵Bristol Myers Squibb, Montreal, QC, Canada
Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
Abstract Number: 2656 • 2015 ACR/ARHP Annual Meeting
Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards
Rieke Alten¹, Robert J. Holt², Jeffrey D. Kent³ and Frank Buttgereit⁴, ¹Charité Univ Medicine, Berlin, Germany, ²College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ³Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ⁴Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Patient reported outcomes such as morning stiffness are reported frequently in rheumatoid arthritis (RA) patients. But little has been reported about the presence and…
Abstract Number: 490 • 2015 ACR/ARHP Annual Meeting
Personalizing the Treat to Target Approach in Rheumatoid Arthritis
Eric M. Ruderman¹, Jennifer Beaumont², Azra Muftic², Arthur M. Mandelin II¹, Amy Eisenstein², George J. Greene² and David Cella², ¹Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The treat to target (T2T) approach has become part of the standard of care in RA management. Implicit in this approach is patient involvement…
Abstract Number: 2735 • 2015 ACR/ARHP Annual Meeting
Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li², E Alemao³, S Deveikis¹ and J Kremer⁵, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: It has been postulated that patients with longstanding RA have more treatment-resistant disease. We propose to examine whether disease duration is an independent predictor…
Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Xin Wang¹, Arthur Kavanaugh², Désirée van der Heijde³, Maxime Dougados⁴, Stefan Florentinus¹, Yihan Li¹, Iain Sainsbury¹ and Josef S. Smolen⁵, ¹AbbVie Inc., North Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴René Descartes University and Hôpital Cochin, Paris, France, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…
Abstract Number: 2743 • 2015 ACR/ARHP Annual Meeting
Treatment Target Status at 6 Months and Long-Term Outcomes at 5 Years: Analysis of Methotrexate-Naïve Patients with Rheumatoid Arthritis
Paul Emery¹, Roy Fleischmann², Stephen Xu³ and Elizabeth C. Hsia^3,4, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ³Janssen Research & Development, LLC, Spring House, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Management guidelines recommend patients (pts) with RA should be treated with the intent of reaching a clinical target of low disease activity or remission…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].